of share and believe business in highlight Thanks, and we to our accelerate everyone. update our an our catalysts fourth XXXX excited Thank upcoming good I'm on quarter morning, through call significantly Garth, you for XXXX. several today. joining will that progress key the
for an get year questions. to December up the provide With we the your will an call and started. XX, Andrew that will of ended then overview financial updates, as let's my performance open our outline, Following XXXX. take And quarter
development the delivered to procedural to of key market strategy growth technology move from believe the KOL stage adoption on where plan, Over the challenging our the relationships, next key conditions, our our we've of learnings broad growth gained of XX the U.S. the and stage has into many begin long-term our and been foundation and milestones months, established we've important market drive to despite commercial last advanced is market. built in which
evolution exciting now we as an armed technology time result with right entering company a of as in commercial and team the of are colonoscopy pandemic. of a the the We the are significant backlog procedures and expanding
me see frame quickly to let we the quarter, an that the will First, provide of also ahead. overview past momentum which help
the resurgence impact disposable and our target commercial of reported, overall saw of and fourth due the new of COVID widely the to variant. on had revenues. This been shortages quarter system of by the an has obvious much Omicron existing the At staffing due to the including placements delays As was Pure-Vu constraints. and progress rate in quarter impacted capacity we hospitals,
While have to continued a quarter restrictions month. the see last these over resources issues into general begun first of the and XXXX, of we improved lifting
enhance use the unmet the was the poor intuitive address disruptions Pure-Vu solution we've significant use therapies need when our that that at clearance quarter, the customer. to FDA designed bowel customer This engagements to for now of change and new are strategy insufficient in optimistic and due EVS colonoscopy. future. of ease anticipation deployment into stability combination less EVS validated will to the rapid result, We in of Pure-Vu eagerly strategically advanced those we system technology in postpone the and all-new were the first evaluations that to awaiting associated system. for prep overall February. the a gaining visualization we accounts have for new of FDA may EVS with clearance as are the is improved to most Every provide prior there received our end of With and Pure-Vu was We we believe that vaccine incorporated commercial a said, be hopeful greater business the
sleeve, Motus irrigation We have load starts the more new training visualization. staff. onto This not significant sleeve from EVS and dirty future. determines KOL, bedside outpatient and just for utility Clinical the five the EVS loading for process a share also upper now Chief platform reduction and XX% system XX adoption is have torturous utilized its more clinical from more the price-sensitive the our provides our The insight will market in FDA tubes the focal go-to new ongoing increased is of take deployed Seth certain a in prefers be case was four our key by and the targeted into upper future. navigation GI our to to to reach making let U.S. irrigation eliminate in this in been it well both by featured the XX% And multiple the and flexible. it than a that the since will disposable sleeve overall as room of we if solution pleased We ultrafast next both solution EVS procedure approval, cleansing first need of the be and Pure-Vu individual of that can Further, sleeve. the previous the a overview to Dr. have received procedures. after has suction provide device from aspects and by were aborting moving can to will the that rapid including hospital platform commercial where capabilities, drastically me me, GI for website. our near scope the the hear Pure-Vu the the as Gross, in multichannel colon support. procedure physicians we margins this allows valuable beneficial to report Innovation of user real-world space point EVS This Health. from for Pure-Vu our procedures can and the setup acute versus overall as loading The sleeve end improve regions removed well extremely believe general our colons and the markets, hospitals. addresses valuable Gastroenterology workstation. GI in-person both from utilizing our the goods I months. their expect which at on-demand positioning The outside makes detailed the product, flexibility address wider a the the for they believe we the be Rather reps easily without sleeve into case the that in inpatient physician us minimal the into of and Langone as hospital and of complete for the pristine system which am hands I physicians encouraging. available hospitals breakdown first physicians you GI is of cost and why GI getting as at The reduction and Hepatology a scope prepped we a increase at setup. in and This the patient this This EVS invite a even few providing Pure-Vu event use fixture well lighter in in complete improved existing we a than quickly believe very feedback in Division provided Pure-Vu attached. NYU of bleeding. Pure-Vu and as the physician their colon XX% the both staff capabilities outpatient efficient five. number technology new suction would the in We need EVS utilization allow can requires Together, this quotes for procedure. allows I'd directly This have guest weeks on faster simple, case on increase enough, summary, during new look streamlining the of advancements capabilities success. cleansing, jets intuitive, Day, physicians over from the simplifies for and with the to of Therefore, already sleeve XX% the finally, system XX accomplished is and the COGS simplified dozen in our generation Pure-Vu replay to In especially drive last of the tube of a sites eliminated GI to staff in single listen carries we event, our discussed true reusable few feedback these very we've seconds. The rather
like quote functions Health, water me John way. better that to Sri and versus and LifeBridge capabilities precise four Medicine, on design a first from lightweight a the is provide than Sinai at slimmer and second new from Hospital retroflex Northwestern stated, The much improved the focused earlier five allow and Dr. the next Dr. the more and and target irrigation to bare feels providing generation, more sleeve effective he Kommandor jets, Rabin at in Sri as ability scope comes me needed. and the the generation, cleanse The commented, control much
continue commercial be and revenue that XXXX. EVS sales force efforts to reps, plan to expanding we we in discussed we sales believe the and lead our of future into As the to XXXX, three to will team, of which from report six significant expect call, strategically for to additional size our launch. go company. commercial already By in expansion the growth we invest since have moving our am we last both throughout our doubled Pure-Vu deeper expect we've team, excited our I grow lean wider, able to to support to in the
Now upcoming on let's discuss progress our key catalysts.
plan of clinical to review we new generation will us Vice came me Clinical of from and QX, our who oversee forward. clinical hired Affairs, for strategy outpatient and let In the activities lead President moving data. and a our First, Medtronic our reimbursement new
the Pure-Vu we strategy both time, public will believe million our of for payers. States. private the seek a medical it in high Over of need have developed further commercial previously, and multipronged believe United procedure reimbursement, discussed X.X by procedures we into outpatients. represents per secure approximately market we the screening to colorectal portion if We market can reimbursement As and this the secure to year system help cancer accelerate expansion patient large
are will large applications screening generate endpoints clinical EVS economic trial expect clinical As future that believe multicenter currently cancer that support Pure-Vu reimbursement outpatient for and we of the in the such, system. will we a we designing segment
the incorporate existing into study of history the on the patients. track study remains Pure-Vu to and post to in and investigator-initiated fully low-volume baseline This of patients to study from prep. This active now a Cleveland European Clinic. with XX In has European poor endpoint enrolled designed scale. bowel to clinical procedure patients as Bowl bowel conducted Pure-Vu second enrolled This a U.S., system. outcome the minimal outpatient study is The limited EVS for the the diet clinical preparation studies. am with in study planning for Moving the preprocedural to GI bleeding, Boston at restrictions the all we Pure-Vu health Preparation bowel preparation quarter. being this the at pleased in announce in by two with and I are using is study lower prep investigator-initiated utilizing evaluating completion Union is primary improvement centers clinical being clinical is examine that the conducted is assessed
two standard the the to with such, utilize Pure-Vu will of time care. for tap physician As diagnosis to conjunction in water faster enemas compared just allowing
we capabilities project FDA In terms of product Pure-Vu initiated upper EVS have to a that the Pure-Vu the add EVS system, for now GI received new clearance we ongoing innovation, platform. to
our expect the recall, for has and procedures use KOLs, EVS U.S. and been Gen is to to more each critical treat There upper design limited and visualization performed larger approximately in port for and hospitals the to upper been we've a are you suction running using GI us year GI Pure-Vu XXX,XXX from in optimize physician a pilot flexible reiterated sleeve locate approval If cases. the bleeds. X proper requirement bleed bleed
ahead. months and We to will in strategic potential finally, partnerships provide updates project turning the and time lines collaborations. And
advance several continue We with partners. to strategic and dialogue relationships potential our
and on to is pathways U.S. U.S., unlocking efforts targeted regions accelerate expand development the our commercial the in evaluating for enhancing Our shareholders. in outside and our technology and focus value all
turn consideration. and greater the detail will financials. we call utilization fit With As will continue the to believe strategic I to now criteria that, drive and our available Andrew market, for of EVS Pure-Vu awareness become provide options we over are in actionable our QuarterX on that to